ストックスクリーナーアプリを入手
54.91
4.71%
2.47
アフターアワーズ：
55.59
0.68
+1.24%
前日終値:
$52.44
開ける：
$53.46
24時間の取引高:
6.46M
Relative Volume:
1.25
時価総額：
$9.77B
収益：
$803.32M
当期純損益:
$-709.10M
株価収益率:
-7.0395
EPS:
-7.8003
ネットキャッシュフロー:
$-212.68M
1週間 パフォーマンス:
-8.21%
1か月 パフォーマンス:
-21.04%
6か月 パフォーマンス:
-1.12%
1年 パフォーマンス:
-15.51%
1日の値動き範囲:
$52.96
$55.55
1週間の範囲:
$49.88
$59.99
52週間の値動き範囲:
$36.22
$104.32
Tempus Ai Inc Stock (TEM) Company Profile
Compare TEM vs VEEV, BTSG, HQY, DOCS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TEM
Tempus Ai Inc
|
54.91 | 9.33B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
VEEV
Veeva Systems Inc
|
183.65 | 30.22B | 3.08B | 860.33M | 1.35B | 5.1463 |
|
BTSG
Brightspring Health Services Inc
|
39.68 | 6.92B | 11.99B | 24.18M | 234.31M | 0.2956 |
|
HQY
Healthequity Inc
|
79.45 | 6.77B | 1.15B | 96.70M | -161.99M | 1.09 |
|
DOCS
Doximity Inc
|
27.73 | 6.27B | 550.17M | 201.35M | 232.07M | 1.00 |
Tempus Ai Inc Stock (TEM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-02 | 再開されました | Morgan Stanley | Overweight |
| 2025-10-21 | ダウングレード | TD Cowen | Buy → Hold |
| 2025-10-20 | 開始されました | Canaccord Genuity | Buy |
| 2025-09-02 | 開始されました | H.C. Wainwright | Buy |
| 2025-04-21 | 開始されました | BTIG Research | Buy |
| 2025-02-25 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2025-02-12 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2025-02-05 | 再開されました | TD Cowen | Buy |
| 2024-12-13 | 開始されました | Wolfe Research | Outperform |
| 2024-12-09 | 開始されました | Guggenheim | Buy |
| 2024-11-11 | ダウングレード | Stifel | Buy → Hold |
| 2024-10-02 | ダウングレード | BofA Securities | Buy → Neutral |
| 2024-08-12 | 開始されました | Piper Sandler | Neutral |
| 2024-07-09 | 開始されました | BofA Securities | Buy |
| 2024-07-09 | 開始されました | JP Morgan | Overweight |
| 2024-07-09 | 開始されました | Longbow | Buy |
| 2024-07-09 | 開始されました | Loop Capital | Buy |
| 2024-07-09 | 開始されました | Morgan Stanley | Overweight |
| 2024-07-09 | 開始されました | Needham | Buy |
| 2024-07-09 | 開始されました | Stifel | Buy |
| 2024-07-09 | 開始されました | TD Cowen | Buy |
| 2024-07-09 | 開始されました | William Blair | Outperform |
すべてを表示
Tempus Ai Inc (TEM) 最新ニュース
Artificial Intelligence Stocks To Follow NowFebruary 6th - MarketBeat
IQ EQ FUND MANAGEMENT IRELAND Ltd Boosts Stock Position in Tempus AI, Inc. $TEM - MarketBeat
Do Tempus AI’s New IPS Results Reframe TEM’s Edge In Precision Oncology Diagnostics? - Yahoo Finance
Best Artificial Intelligence Stocks To ResearchFebruary 5th - MarketBeat
Can Tempus AI’s (TEM) Immune Profile Score Redefine Its Edge In Precision Oncology Data? - simplywall.st
Tempus AI Links Hereditary Cancer Data And Immune Scoring To Growth Prospects - Yahoo Finance
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - The Globe and Mail
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - The Motley Fool
Tempus AI, Inc. (TEM): A Bull Case Theory - Finviz
Insider Sell: David Epstein Sells 370 Shares of Tempus AI Inc (T - GuruFocus
Tempus AI (NASDAQ:TEM) Director Sells $21,981.70 in Stock - MarketBeat
Promising Artificial Intelligence Stocks To Watch NowFebruary 4th - MarketBeat
RSI Alert: Tempus AI (TEM) Now Oversold - Nasdaq
Tempus AI Stock (TEM) Opinions on Q4 Earnings Beat - Quiver Quantitative
New DNA study could sharpen cancer risk for thousands of patients - stocktitan.net
Tempus AI, Inc. (NASDAQ:TEM) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
AI in Oncology Market to Reach US$ 22.85 Billion by 2033, Growing - openPR.com
Best Artificial Intelligence Stocks To Watch TodayFebruary 2nd - MarketBeat
Tempus AI, Inc. (TEM) Investor Outlook: Navigating a 46.97% Upside Amidst High Growth and Strategic Collaborations - DirectorsTalk Interviews
What's Going On With Tempus AI Stock Monday?Tempus AI (NASDAQ:TEM) - Benzinga
RNA in cancer gene tests found 1 in 25 positives otherwise missed - stocktitan.net
Artificial Intelligence Stocks To Keep An Eye OnFebruary 1st - MarketBeat
Tempus AI, Inc. (TEM) Strengthens Precision Medicine with New Tools, Partnerships, and Growth Milestones - Finviz
Mirae Asset Global Investments Co. Ltd. Increases Stake in Tempus AI, Inc. $TEM - MarketBeat
Artificial Intelligence Stocks To Follow TodayJanuary 31st - MarketBeat
Insider Selling: Tempus AI (NASDAQ:TEM) CEO Sells 166,250 Shares of Stock - MarketBeat
Promising Artificial Intelligence Stocks To Watch TodayJanuary 30th - MarketBeat
Tempus AI Enhances AI-Driven Diagnostics With Multiple FDA Approvals - MSN
Tempus AI Inc (TEM) Trading Down 4.09% on Jan 30 - GuruFocus
Esoteric Testing Research Report 2026 - GlobeNewswire Inc.
Is Tempus AI Inc. stock a good dividend stockWeekly Trade Review & Community Verified Swing Trade Signals - mfd.ru
Tempus AI's COO Ryan Fukushima sells shares worth $2.27 million - MSN
Artificial Intelligence Stocks Worth WatchingJanuary 29th - MarketBeat
Top Artificial Intelligence Stocks To Watch TodayJanuary 3rd - MarketBeat
TEM vs. DOCS: Which Medical-Tech Stock Looks Promising Amid AI Boom? - Finviz
21,000 Shares in Tempus AI, Inc. $TEM Purchased by Hussman Strategic Advisors Inc. - MarketBeat
Should Tempus AI’s (TEM) New Immunotherapy Prediction Data Shift How Investors View Its Moat? - simplywall.st
Tempus AI (TEM) Valuation Check After New Immune Profile Score Data And High Profile Investor Interest - Yahoo Finance
Tempus AI study shows improved cancer immunotherapy prediction By Investing.com - Investing.com Australia
Tempus AI Expands Cancer Tools As Shares Trade Below Analyst Estimates - Yahoo Finance
Tempus AI’s Clinical Breakthrough: A Potential Catalyst for Growth - AD HOC NEWS
Tempus AI IPS Study Points To Wider Immunotherapy Use And Investor Interest - simplywall.st
Is It Time To Reassess Tempus AI (TEM) After Its Strong 1 Year Share Price Run? - Yahoo Finance UK
Tempus says AI-powered biomarker improves immunotherapy predictions - FirstWord Pharma
Artificial Intelligence Stocks To Watch NowJanuary 27th - MarketBeat
Promising Artificial Intelligence Stocks To Follow TodayJanuary 4th - MarketBeat
Nancy Pelosi Just Doubled Down on AI Again - Yahoo Finance
Tempus Says Study Shows AI-Driven Test More Accurately Predicts Immunotherapy Benefits - marketscreener.com
Tempus Ai, Inc. Reveals Its AI-Driven IPS Test More Accurately Predicts Immunotherapy Benefit Compared to Conventional Biomarkers - marketscreener.com
Tempus AI study shows improved cancer immunotherapy prediction - Investing.com
Tempus Reveals Its AI-Driven IPS Test More Accurately Predicts Immunotherapy Benefit Compared to Conventional Biomarkers - Business Wire
Tempus Ai Inc (TEM) 財務データ
収益
当期純利益
現金流量
EPS
3.44%
16.78%
大文字化:
|
ボリューム (24 時間):